Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment (RESERVIH32)

Centre Hospitalier Universitaire de Nīmes

Status: Active, not recruiting

Conditions: HIV-1-infection

Treatments: Other: Bioclinical evaluation

Study type: Observational

Funder types: Other

Identifiers

NCT03940521

NIMAO/2018-02/PC-01

Details and patient eligibility

About

The authors hypothesize that there is a correlation between the percentage of CD4+ T cells expressing CD32a and/or X and the quantity of DNA found in peripheral blood mononuclear cells in patients infected with HIV-1. Also, that there is a correlation between expression of CD32a and/or X and proviral load.

Enrollment: 48 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient infected with aviremic HIV-1 (<20 copies of HIV-1 RNA/ml plasma) undergoing antiretroviral treatment for at least 2 years
• Patient has known duration of infection and treatment
• Patient has known pretherapeutic CD4+ T cell count and viremia
• Patient has known CD4+ T cell count, residual viremia and CD4/CD8 ratio for previous 2 years
• Patient weighs at least 56kg
• The patient is not opposed to their inclusion in the study
• The patient must be a member or beneficiary of a health insurance plan
• Patient at least 18 years old

Exclusion criteria

• Patient has an acute infection
• The subject has already been included in the study or is in a period of exclusion determined by a previous study
• It is impossible to give the subject informed information
• The patient is under safeguard of justice or state guardianship
• Patient is pregnant, parturient or breastfeeding

Trial design

48 participants in 1 patient group

HIV-A infected patients

Treatment:

Other: Bioclinical evaluation